68Ga PET/CT scan for prostate cancer imaging
Part of Cancer clinical trials.
This trial looks at a specific PET/CT scan using a tracer called 68Ga to create detailed images of prostate cancer. It may help doctors see where cancer is in the body more clearly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have confirmed or suspected cancer
- Have a prostate cancer concern (confirmed or suspected)
- Agree to take part and sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at using a specific PET/CT scan (a whole-body imaging test) to help evaluate cancer that is confirmed or suspected. If you are eligible, you may receive this scan soon after a recent FDG PET/CT to compare or improve how cancers are identified.
This trial studies how well a specific PET/CT scan using a radioactive tracer can detect or evaluate cancers. It may help doctors see where cancer is in the body more clearly.
This trial tests a new radioactive tracer called 68Ga-SFB6-ZN01 for PET/CT scans in people with suspected or confirmed solid tumors. It aims to see if this tracer can help find cancer or detect recurrence after treatment.
This early-phase study tests special PET/CT scans using a radioactive tracer to see cancer areas that have specific targets. It may help doctors better visualize tumors and plan next steps, using scans that you may already be familiar with (FDG) plus targeted tracers.
This trial looks at prostate cancer patients who have not started treatment yet and have two different PET/CT scans close together. It may help doctors compare how these scans show prostate cancer in the body.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.